The effect of oxytocin nasal spray on social interaction deficits observed in young children with autism: a randomized clinical crossover trial

C J Yatawara, S L Einfeld, I B Hickie, T A Davenport, A J Guastella, C J Yatawara, S L Einfeld, I B Hickie, T A Davenport, A J Guastella

Abstract

Interventions for autism are limited. The synthetic hormone oxytocin may provide a potential treatment to improve core social and behavioral difficulties in autism, but its efficacy has yet to be evaluated in young children who potentially may benefit to a greater extent. We investigated the efficacy, tolerability and safety of oxytocin treatment in young children with autism using a double-blind, randomized, placebo-controlled, crossover, clinical trial. Thirty-one children with autism received 12 International Units (IU) of oxytocin and placebo nasal spray morning and night (24 IU per day) for 5 weeks, with a 4-week washout period between each treatment. Compared with placebo, oxytocin led to significant improvements on the primary outcome of caregiver-rated social responsiveness. Overall, nasal spray was well tolerated, and the most common reported adverse events were thirst, urination and constipation. This study is the first clinical trial to support the potential of oxytocin as an early intervention for young children with autism to help improve social interaction deficits.

Figures

Figure 1
Figure 1
Consort diagram of study participants by randomization schedule. Parents of 64 children initially contacted the Brain and Mind Centre (BMC) to enquire about the study, of which 44 children were screened for eligibility. Thirty-nine children entered the randomization schedule, and 32 (82%) completed phase 1 and then crossed-over to phase 2. One participant was excluded before completion of phase 2 because of time commitments in following the protocol. The final number of participants included in the analyses was 31, including 15 randomized to ‘oxytocin then placebo' and 16 to ‘placebo then oxytocin'.
Figure 2
Figure 2
Plotting mean scores on the primary (caregiver-rated Social Responsiveness Scale (SRS-P), caregiver-rated Repetitive Behavior Scale-Revised (RBS-R-P)) and secondary (caregiver-rated Developmental Behavior Checklist (DBC-P)) outcome measures by time and condition, N=31.
Figure 3
Figure 3
Caregiver-rated Social Responsiveness Scale (SRS-P) pre- and post-test scores after oxytocin (red triangles) and placebo (black triangles), N=31. The solid diagonal line represents ‘line of no change' and the dotted lines upper and lower Reliable Change Index (RCI) confidence limits. Test-retest reliability=0.84; s.d. for the pretest=22.6.

References

    1. Association APDiagnostic and Statistical Manual of Mental Disorders, 4th edn. Text Revision. American Psychiatric Association: Washington DC, USA, 2000.
    1. Autism Spectrum Disorders. Available at: (last accessed date 20th November 2014).
    1. Sharma A, Shaw SR. Efficacy of risperidone in managing maladaptive behaviors for children with autistic spectrum disorder: a meta-analysis. J Pediatr Health Care 2012; 26: 291–299.
    1. Gibbs TT Pharmacological treatment of autism. In: GJ Blatt (ed). The Neurochemical Basis of Autism. Springer: : Boston, MA, USA, 2010, pp 245–267.
    1. Reichow B, Barton EE, Boyd BA, Hume K. Early intensive behavioral intervention (EIBI) for young children with autism spectrum disorders (ASD). Cochrane Database Syst Rev 2012; 10: CD009260.
    1. Howlin P, Baron-Cohen S, Hadwin J. Teaching Children with Autism to Mind-read: A Practical Guide. Wiley: : New York, NY, USA, 1999.
    1. Howlin P, Udwin O. Outcomes in Neurodevelopmental and Genetic Disorders. Cambridge University Press: : Cambridge, MA, USA, 2002.
    1. Guastella AJ, MacLeod C. A critical review of the influence of oxytocin nasal spray on social cognition in humans: Evidence and future directions. Horm Behav 2012; 61: 410–418.
    1. Donaldson ZR, Young LJ. Oxytocin, vasopressin, and the neurogenetics of sociality. Science 2008; 322: 900–904.
    1. Guastella AJ, Mitchell PB, Dadds MR. Oxytocin increases gaze to the eye-region of human faces. Biol Psychiatry 2008; 63: 3–5.
    1. Schulze L, Lischke A, Greif J, Herpertz SC, Heinrichs M, Domes G. Oxytocin increases recognition of masked emotional faces. Psychoneuroendocrinology 2011; 36: 1378–1382.
    1. Lischke A, Berger C, Prehn K, Heinrichs M, Herpertz SC, Domes G. Intranasal oxytocin enhances emotion recognition from dynamic facial expressions and leaves eye-gaze unaffected. Psychoneuroendocrinology 2012; 37: 475–481.
    1. Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature 2005; 435: 673–676.
    1. Guastella AJ, Hickie IB. Oxytocin treatment, circuitry and autism: a critical review of the literature placing oxytocin into the autism context. Biol Psychiatry 2015; pii: S0006-3223 (15) 00543-0.
    1. Hollander E, Novotny S, Hanratty M, Yaffe R, Decaria CM. Oxytocin infusion reduces repetitive behaviours in adults with Autistic and Asperser's disorders. Neuropsychoparmacology 2003; 28: 193–198.
    1. Hollander E, Bartz J, Chaplin W, Phillips A, Sumner J, Soorya L et al. Oxytocin increases retention of social cognition in autism. Biol Psychiatry 2007; 61: 498–503.
    1. Guastella AJ, Hickie IB, McGuinness MM, Otis M, Woods EA, Disinger HM et al. Recommendations for the standardisation of oxytocin nasal administration and guidelines for its reporting in human research. Psychoneuroendocrinology 2013; 38: 612–625.
    1. Andari E, Duhamel J-R, Zalla T, Herbrecht E, Leboyer M, Sirigu A. Promoting social behavior with oxytocin in high-functioning autism spectrum disorders. Horm Behav 2010; 107: 4389–4394.
    1. Anagnostou E, Soorya L, Chaplin W, Bartz JA, Halpern D, Wasserman S et al. Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. Mol Autism 2012; 3: 16.
    1. Guastella AJ, Einfeld SL, Gray KM, Rinehart NJ, Tonge BJ, Lambert TJ et al. Intranasal oxytocin improves emotion recognition for youth with autism spectrum disorders. Biol Psychiatry 2010; 67: 692–694.
    1. Rogers SJ. Brief Report: early intervention in autism. J Autism Dev Disord 1996; 26: 243–246.
    1. Harris SL, Handleman JS. Age and IQ at intake as predictors of placement for young children with autism: a four- to six-year follow-up. J Autism Dev Disord 2000; 30: 137–142.
    1. Lord C, Rutter M, Goode S, Heemsbergen J, Jordan H, Mawhood L et al. Austism diagnostic observation schedule: a standardized observation of communicative and social behavior. J Autism Dev Disord 1989; 19: 185–212.
    1. Constantino JN. The Social Responsiveness Scale. Western Psychological Services:: Los Angele, CA, USA, 2005.
    1. Pine E, Luby J, Abbacchi A, Constantino JN. Quantitative assessment of autistic symptomatology in preschoolers. Autism 2006; 10: 344–352.
    1. Einfeld S, Tonge B. The Developmental Behavior Checklist: the development and validation of an instrument to assess behavioral and emotional disturbance in children and adolescents with mental retardation. J Autism Dev Disord 1995; 25: 81–104.
    1. Einfeld SL, Tonge BT. Manual for the Developmental Behaviour Checklist (Second Edition)-Primary Carer Version (DBC-P-P) and Teacher Version (DBC-P-T). Monash University Centre for Developmental Psychiatry and Psychology and School of Psychiatry, University of New South Wales: : Melbourne and Sydney, Australia, 2002.
    1. Roid GH, Miller LJ. Leiter International Performance Scare-Revised. Stoeling: : Wooddale, IL, USA, 1997.
    1. Bodfish JW, Symons FJ, Parker DE, Lewis MH. Varieties of repetitive behavior in autism: comparisons to mental retardation. J Autism Dev Disord 2000; 30: 237–243.
    1. Brereton AV, Tonge BJ, Einfeld SL. Psychopathology in children and adolescents with autism compared to young people with intellectual disability. J Autism Dev Disord 2006; 36: 863–870.
    1. Guy W. ECDEU Assessment Manual for Psychopharmacology. US Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration: : Rockville, MD, USA, 1976.
    1. Brannan AM, Heflinger CA. The Caregiver Strain Questionnaire: measuring the impact on the family of living with a child with serious emotional disturbance. J Emot Behav Disord 1997; 5: 212–223.
    1. Cohen J. A power primer. Psychol Bull 1992; 112: 155–159.
    1. Jacobson NS, Truax P. Clinical significance: a statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991; 59: 12–19.
    1. Birmaher B, Waterman GS, Ryan ND, Perel J, McNabb J, Balach L et al. Randomized, controlled trial of amitriptyline versus placebo for adolescents with 'treatment-resistant' major depression. J Am Acad Child Adolesc Psychiatry 1998; 37: 527–535.
    1. King BH, Dukes K, Donnelly CL, Sikich L, McCracken JT, Scahill L et al. Baseline factors predicting placebo response to treatment in children and adolescents with autism spectrum disorders: a multisite randomized clinical trial. JAMA Pediatr 2013; 167: 1045–1052.
    1. Masi A, Amit L, Glozier N, Hickie IB, Guastella AJ. Predictors of placebo response in pharmacological and dietary supplement treatment trials in pediatric autism spectrum disorder: a meta-analysis. Transl Psychiatry 2015; 5: e640.
    1. Dadds MR, MacDonald E, Cauchi A, Williams K, Levy F, Brennan J. Nasal oxytocin for social deficits in childhood autism: a randomized controlled trial. J Autism Dev Disord 2013; 44: 521–531.
    1. Guastella A, Gray K, Rinehart N, Alvares G, Tonge B, Hickie I et al. A randomized controlled trial of a course of intranasal oxytocin to treat youth diagnosed with autism. J Child Psychol Psychiatry 2015; 56: 444–452.
    1. Miller G. The promise and perils of oxytocin. Science 2013; 339: 267–269.
    1. Young LJ. When too much of a good thing is bad: chronic oxytocin, development, and social impairments. Biol Psychiatry 2013; 74: 160–161.
    1. Chou C, DiGiovanni SR, Mejia R, Nielsen S, Knepper M. Oxytocin as an antidiuretic hormone. I. Concentration dependence of action. Am J Physiol 1995; 269: F70–F77.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다